What does a modified-Fibonacci dose-escalation actually correspond to?

BACKGROUND: In most phase I oncology trials, it is often stated that the dose increments follow a “modified-Fibonacci sequence”. This term, however, is vague. METHODS: To better characterize this sequence, we reviewed 81 phase I trials based on this concept. RESULTS: Out of 198 phase I oncology tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Penel, Nicolas, Kramar, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538691/
https://www.ncbi.nlm.nih.gov/pubmed/22824322
http://dx.doi.org/10.1186/1471-2288-12-103
_version_ 1782254994712428544
author Penel, Nicolas
Kramar, Andrew
author_facet Penel, Nicolas
Kramar, Andrew
author_sort Penel, Nicolas
collection PubMed
description BACKGROUND: In most phase I oncology trials, it is often stated that the dose increments follow a “modified-Fibonacci sequence”. This term, however, is vague. METHODS: To better characterize this sequence, we reviewed 81 phase I trials based on this concept. RESULTS: Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35…. The “modified Fibonacci-sequence” gathers heterogeneous variation of the genuine sequence, which does not tend to a constant number at higher dose-levels. CONCLUSION: This confusing term should be avoided.
format Online
Article
Text
id pubmed-3538691
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35386912013-01-10 What does a modified-Fibonacci dose-escalation actually correspond to? Penel, Nicolas Kramar, Andrew BMC Med Res Methodol Research Article BACKGROUND: In most phase I oncology trials, it is often stated that the dose increments follow a “modified-Fibonacci sequence”. This term, however, is vague. METHODS: To better characterize this sequence, we reviewed 81 phase I trials based on this concept. RESULTS: Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35…. The “modified Fibonacci-sequence” gathers heterogeneous variation of the genuine sequence, which does not tend to a constant number at higher dose-levels. CONCLUSION: This confusing term should be avoided. BioMed Central 2012-07-23 /pmc/articles/PMC3538691/ /pubmed/22824322 http://dx.doi.org/10.1186/1471-2288-12-103 Text en Copyright ©2012 Penel and Kramar; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Penel, Nicolas
Kramar, Andrew
What does a modified-Fibonacci dose-escalation actually correspond to?
title What does a modified-Fibonacci dose-escalation actually correspond to?
title_full What does a modified-Fibonacci dose-escalation actually correspond to?
title_fullStr What does a modified-Fibonacci dose-escalation actually correspond to?
title_full_unstemmed What does a modified-Fibonacci dose-escalation actually correspond to?
title_short What does a modified-Fibonacci dose-escalation actually correspond to?
title_sort what does a modified-fibonacci dose-escalation actually correspond to?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538691/
https://www.ncbi.nlm.nih.gov/pubmed/22824322
http://dx.doi.org/10.1186/1471-2288-12-103
work_keys_str_mv AT penelnicolas whatdoesamodifiedfibonaccidoseescalationactuallycorrespondto
AT kramarandrew whatdoesamodifiedfibonaccidoseescalationactuallycorrespondto

Ejemplares similares